Abstract
The pineal and retinal melatonin regulates endogenous circadian rhythms, and has various physiological functions including neuromodulatory and vasoactive actions, antioxidative and neuroprotective properties. We have previously demonstrated that the melatonin 1a-receptor (MT1) is localized in human retinal cells and that the expression of MT1 is increased in Alzheimer ’ s disease (AD) patients. We now present the first immunohistochemical evidence for the cellular distribution of the second melatonin receptor, MT2, in the human retina and in AD patients. In elderly controls, MT2 was localized to ganglion and bipolar cells in the inner nuclear layer, and to the inner segments of the photoreceptor cells. In addition, cellular processes in inner and outer plexiform layers were strongly positive for MT2. In AD patients the overall intensity of MT2-staining was distinctly decreased in all observed cellular localizations. Our results indicate that MT2 in the humans, similar to MT1, may indeed be involved in transmitting melatonin ’ s effects in the retina, and AD pathology may impair MT2 expression. Since our previous results showed an increase in MT1 expression in AD retina, the two melatonin receptor subtypes appear to be differentially affected by the course of the neurodegenerative disorder.
Keywords: Melatonin receptor, MT2, Retina, Alzheimer's disease
Current Alzheimer Research
Title: The MT2 Melatonin Receptor Subtype is Present in Human Retina and Decreases in Alzheimers Disease
Volume: 4 Issue: 1
Author(s): Egemen Savaskan, Ralf Jockers, Mohammed Ayoub, Debora Angeloni, Franco Fraschini, Josef Flammer, Anne Eckert, Franz Muller-Spahn and Peter Meyer
Affiliation:
Keywords: Melatonin receptor, MT2, Retina, Alzheimer's disease
Abstract: The pineal and retinal melatonin regulates endogenous circadian rhythms, and has various physiological functions including neuromodulatory and vasoactive actions, antioxidative and neuroprotective properties. We have previously demonstrated that the melatonin 1a-receptor (MT1) is localized in human retinal cells and that the expression of MT1 is increased in Alzheimer ’ s disease (AD) patients. We now present the first immunohistochemical evidence for the cellular distribution of the second melatonin receptor, MT2, in the human retina and in AD patients. In elderly controls, MT2 was localized to ganglion and bipolar cells in the inner nuclear layer, and to the inner segments of the photoreceptor cells. In addition, cellular processes in inner and outer plexiform layers were strongly positive for MT2. In AD patients the overall intensity of MT2-staining was distinctly decreased in all observed cellular localizations. Our results indicate that MT2 in the humans, similar to MT1, may indeed be involved in transmitting melatonin ’ s effects in the retina, and AD pathology may impair MT2 expression. Since our previous results showed an increase in MT1 expression in AD retina, the two melatonin receptor subtypes appear to be differentially affected by the course of the neurodegenerative disorder.
Export Options
About this article
Cite this article as:
Savaskan Egemen, Jockers Ralf, Ayoub Mohammed, Angeloni Debora, Fraschini Franco, Flammer Josef, Eckert Anne, Muller-Spahn Franz and Meyer Peter, The MT2 Melatonin Receptor Subtype is Present in Human Retina and Decreases in Alzheimers Disease, Current Alzheimer Research 2007; 4 (1) . https://dx.doi.org/10.2174/156720507779939823
DOI https://dx.doi.org/10.2174/156720507779939823 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subject Index to Volume 2
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Role of Transcription Factors in the Formation of an Arrhythmogenic Substrate in Congestive Human Heart Failure
Current Medicinal Chemistry Hemodynamic Regulation of Metallopeptidases within the Vasculature
Protein & Peptide Letters Cardiovascular Side Effects of New Antidepressants and Antipsychotics: New Drugs, old Concerns?
Current Pharmaceutical Design Cardiac Stem Cell Regeneration in Metabolic Syndrome
Current Pharmaceutical Design Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications
Current Molecular Pharmacology Suppression of NF-κB Signaling and P-glycoprotein Function by Gambogic Acid Synergistically Potentiates Adriamycin -induced Apoptosis in Lung Cancer
Current Cancer Drug Targets Influence of a High-Fat Diet on Cardiac iNOS in Female Rats
Current Vascular Pharmacology Resurgence of Herbal Antihypertensives in Management of Hypertension
Current Hypertension Reviews Inhibition of Sphingomyelin Hydrolysis: Targeting the Lipid Mediator Ceramide as a Key Regulator of Cellular Fate
Current Medicinal Chemistry Clinical Management of Diabetes Mellitus in the Older Adult Patient
Current Diabetes Reviews Acute Kidney Injury in Pediatric Heart Failure
Current Cardiology Reviews Editorial: [Hot Topic: Antidotes and Rescue Therapies]
Current Pharmaceutical Biotechnology Advances in Analyses of Profens in Biological and Environmental Samples by Liquid Chromatography
Current Pharmaceutical Analysis Endothelin and Subarachnoid Hemorrhage-Induced Cerebral Vasospasm: Pathogenesis and Treatment
Current Medicinal Chemistry Ranolazine, a Partial Fatty Acid Oxidation Inhibitor, its Potential Benefit in Angina and Other Cardiovascular Disorders
Recent Patents on Cardiovascular Drug Discovery Human Sirtuins: An Overview of an Emerging Drug Target in Age-Related Diseases and Cancer
Current Drug Targets Development and Validation of a Simple LC-UV Method to Assay Doxazosin in Polymeric Nanocapsules and Tablets
Current Pharmaceutical Analysis Post-traumatic Stress Disorder in Heart Failure Patients: A Test of the Cardiac Disease-induced PTSD Hypothesis
Current Psychiatry Research and Reviews Review and Research on Feature Selection Methods from NMR Data in Biological Fluids. Presentation of an Original Ensemble Method Applied to Atherosclerosis Field
Current Drug Metabolism